ETERNA THERAPEUTICS INC (ERNA)

US1140822099 - Common Stock

2.4  +0.16 (+7.14%)

Fundamental Rating

0

ERNA gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 592 industry peers in the Biotechnology industry. ERNA may be in some trouble as it scores bad on both profitability and health. ERNA is valued expensive and it does not seem to be growing.



1

1. Profitability

1.1 Basic Checks

ERNA had negative earnings in the past year.
In the past year ERNA has reported a negative cash flow from operations.
In the past 5 years ERNA always reported negative net income.
The reported operating cash flow has been mixed in the past 5 years: ERNA reported negative operating cash flow in multiple years.

1.2 Ratios

Looking at the Return On Assets, with a value of -38.33%, ERNA is in the better half of the industry, outperforming 62.76% of the companies in the same industry.
ERNA's Return On Equity of -562.64% is on the low side compared to the rest of the industry. ERNA is outperformed by 82.31% of its industry peers.
Industry RankSector Rank
ROA -38.33%
ROE -562.64%
ROIC N/A
ROA(3y)-205.75%
ROA(5y)-126.74%
ROE(3y)-401.65%
ROE(5y)-249.89%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

ERNA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

0

2. Health

2.1 Basic Checks

The number of shares outstanding for ERNA has been increased compared to 1 year ago.
ERNA has more shares outstanding than it did 5 years ago.
The debt/assets ratio for ERNA is higher compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of -6.00, we must say that ERNA is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -6.00, ERNA is not doing good in the industry: 68.71% of the companies in the same industry are doing better.
ERNA has a Debt/Equity ratio of 1.43. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of ERNA (1.43) is worse than 81.97% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.43
Debt/FCF N/A
Altman-Z -6
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

ERNA has a Current Ratio of 0.73. This is a bad value and indicates that ERNA is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of ERNA (0.73) is worse than 92.69% of its industry peers.
ERNA has a Quick Ratio of 0.73. This is a bad value and indicates that ERNA is not financially healthy enough and could expect problems in meeting its short term obligations.
ERNA has a worse Quick ratio (0.73) than 92.35% of its industry peers.
Industry RankSector Rank
Current Ratio 0.73
Quick Ratio 0.73

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 60.15% over the past year.
EPS 1Y (TTM)60.15%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q58.63%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

0

4. Valuation

4.1 Price/Earnings Ratio

ERNA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

ERNA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

ETERNA THERAPEUTICS INC

NASDAQ:ERNA (3/28/2024, 1:10:00 PM)

2.4

+0.16 (+7.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap12.98M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -38.33%
ROE -562.64%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 1.43
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 0.73
Quick Ratio 0.73
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)60.15%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next YN/A
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y